Thomas K. Equels - Net Worth and Insider Trading

Thomas K. Equels Net Worth

The estimated net worth of Thomas K. Equels is at least $372,962 dollars as of 2024-11-07. Thomas K. Equels is the CEO & President of AIM ImmunoTech Inc and owns about 1,493,042 shares of AIM ImmunoTech Inc (AIM) stock worth over $372,962. Details can be seen in Thomas K. Equels's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas K. Equels has not made any transactions after 2024-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Thomas K. Equels

To

Thomas K. Equels Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Thomas K. Equels owns 1 companies in total, including AIM ImmunoTech Inc (AIM) .

Click here to see the complete history of Thomas K. Equels’s form 4 insider trades.

Insider Ownership Summary of Thomas K. Equels

Ticker Comapny Transaction Date Type of Owner
AIM AIM ImmunoTech Inc 2024-09-16 director & Vice Chairman of Board

Thomas K. Equels Latest Holdings Summary

Thomas K. Equels currently owns a total of 1 stock. Thomas K. Equels owns 1,493,042 shares of AIM ImmunoTech Inc (AIM) as of September 16, 2024, with a value of $372,962.

Latest Holdings of Thomas K. Equels

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AIM AIM ImmunoTech Inc 2024-09-16 1,493,042 0.25 372,962

Holding Weightings of Thomas K. Equels


Thomas K. Equels Form 4 Trading Tracker

According to the SEC Form 4 filings, Thomas K. Equels has made a total of 15 transactions in AIM ImmunoTech Inc (AIM) over the past 5 years, including 15 buys and 0 sells. The most-recent trade in AIM ImmunoTech Inc is the acquisition of 5,000 shares on September 16, 2024, which cost Thomas K. Equels around $1,500.

Insider Trading History of Thomas K. Equels

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Thomas K. Equels Trading Performance

GuruFocus tracks the stock performance after each of Thomas K. Equels's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas K. Equels is -16.79%. GuruFocus also compares Thomas K. Equels's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas K. Equels within 3 months outperforms 5 times out of 27 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Thomas K. Equels's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Thomas K. Equels

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 24 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -0.39 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -1.2 LIMIT LIMIT LIMIT LIMIT LIMIT

Thomas K. Equels Ownership Network

Ownership Network List of Thomas K. Equels

No Data

Ownership Network Relation of Thomas K. Equels

Insider Network Chart

Thomas K. Equels Owned Company Details

What does AIM ImmunoTech Inc do?

Who are the key executives at AIM ImmunoTech Inc?

Thomas K. Equels is the director & Vice Chairman of Board of AIM ImmunoTech Inc. Other key executives at AIM ImmunoTech Inc include CFO Ellen M Lintal , other: Medical Director David R Strayer , and VP of Operations Wayne S. Springate .

AIM ImmunoTech Inc (AIM) Insider Trades Summary

Over the past 18 months, Thomas K. Equels made 9 insider transaction in AIM ImmunoTech Inc (AIM) with a net purchase of 259,189. Other recent insider transactions involving AIM ImmunoTech Inc (AIM) include a net purchase of 68,744 shares made by Rodino Peter W. Iii , a net purchase of 90,910 shares made by Stewart Appelrouth , and a net purchase of 38,462 shares made by Nancy Bryan .

In summary, during the past 3 months, insiders sold 0 shares of AIM ImmunoTech Inc (AIM) in total and bought 25,000 shares, with a net purchase of 25,000 shares. During the past 18 months, 0 shares of AIM ImmunoTech Inc (AIM) were sold and 457,305 shares were bought by its insiders, resulting in a net purchase of 457,305 shares.

AIM ImmunoTech Inc (AIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

AIM ImmunoTech Inc Insider Transactions

No Available Data

Thomas K. Equels Mailing Address

Above is the net worth, insider trading, and ownership report for Thomas K. Equels. You might contact Thomas K. Equels via mailing address: 2117 Southwest Highway 484, Ocala Fl 34473.